270 related articles for article (PubMed ID: 21485696)
21. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.
Mulder H; Herder A; Wilmink FW; Tamminga WJ; Belitser SV; Egberts AC
Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):107-14. PubMed ID: 16294366
[TBL] [Abstract][Full Text] [Related]
22. Evidence based drug dosing and pharmacotherapeutic recommendations per genotype.
Deneer VH; van Schaik RH
Methods Mol Biol; 2013; 1015():345-54. PubMed ID: 23824868
[TBL] [Abstract][Full Text] [Related]
23. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
Zhou SF; Liu JP; Chowbay B
Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
[TBL] [Abstract][Full Text] [Related]
24. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity.
Ingelman-Sundberg M
Pharmacogenomics J; 2005; 5(1):6-13. PubMed ID: 15492763
[TBL] [Abstract][Full Text] [Related]
25. Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine.
Bernal ML; Sinues B; Johansson I; McLellan RA; Wennerholm A; Dahl ML; Ingelman-Sundberg M; Bertilsson L
Pharmacogenetics; 1999 Oct; 9(5):657-60. PubMed ID: 10591547
[No Abstract] [Full Text] [Related]
26. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects.
Wuttke H; Rau T; Heide R; Bergmann K; Böhm M; Weil J; Werner D; Eschenhagen T
Clin Pharmacol Ther; 2002 Oct; 72(4):429-37. PubMed ID: 12386645
[TBL] [Abstract][Full Text] [Related]
27. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
Evans WE; Relling MV
Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
[TBL] [Abstract][Full Text] [Related]
28. The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants.
Sjöqvist F; Eliasson E
Clin Pharmacol Ther; 2007 Jun; 81(6):899-902. PubMed ID: 17392719
[TBL] [Abstract][Full Text] [Related]
29. Pharmacogenomics in Alzheimer's disease.
Cacabelos R
Methods Mol Biol; 2008; 448():213-357. PubMed ID: 18370236
[TBL] [Abstract][Full Text] [Related]
30. Genetic polymorphism of CYP2D6 in the Japanese population.
Chida M; Yokoi T; Kosaka Y; Chiba K; Nakamura H; Ishizaki T; Yokota J; Kinoshita M; Sato K; Inaba M; Aoki Y; Gonzalez FJ; Kamataki T
Pharmacogenetics; 1999 Oct; 9(5):601-5. PubMed ID: 10591540
[TBL] [Abstract][Full Text] [Related]
31. [Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].
Szewczuk-Bogusławska M; Grzesiak M; Beszłej JA; Kiejna A
Psychiatr Pol; 2004; 38(6):1093-104. PubMed ID: 15779673
[TBL] [Abstract][Full Text] [Related]
32. Determination of CYP2D6 gene copy number by multiplex polymerase chain reaction analysis.
Leandro-García LJ; Leskelä S; Montero-Conde C; Landa I; López-Jimenez E; Letón R; Seeringer A; Kirchheiner J; Cascón A; Robledo M; Rodríguez-Antona C
Anal Biochem; 2009 Jun; 389(1):74-6. PubMed ID: 19303860
[TBL] [Abstract][Full Text] [Related]
33. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
Fux R; Mörike K; Pröhmer AM; Delabar U; Schwab M; Schaeffeler E; Lorenz G; Gleiter CH; Eichelbaum M; Kivistö KT
Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of a high-throughput genetic analysis in the identification of responders/non-responders to CYP2D6-metabolized drugs.
Savino M; Seripa D; Gallo AP; Garrubba M; D'Onofrio G; Bizzarro A; Paroni G; Paris F; Mecocci P; Masullo C; Pilotto A; Santini SA
Clin Lab; 2011; 57(11-12):887-93. PubMed ID: 22239018
[TBL] [Abstract][Full Text] [Related]
35. Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study.
Kawanishi C; Lundgren S; Agren H; Bertilsson L
Eur J Clin Pharmacol; 2004 Jan; 59(11):803-7. PubMed ID: 14652703
[TBL] [Abstract][Full Text] [Related]
36. Rapid and comprehensive determination of cytochrome P450 CYP2D6 poor metabolizer genotypes by multiplex polymerase chain reaction.
Roberts R; Joyce P; Kennedy MA
Hum Mutat; 2000; 16(1):77-85. PubMed ID: 10874309
[TBL] [Abstract][Full Text] [Related]
37. Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship.
Dorado P; Berecz R; Cáceres MC; González I; Cobaleda J; Llerena A
Clin Chem Lab Med; 2005; 43(3):275-9. PubMed ID: 15843230
[TBL] [Abstract][Full Text] [Related]
38. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.
Bertilsson L; Dahl ML; Dalén P; Al-Shurbaji A
Br J Clin Pharmacol; 2002 Feb; 53(2):111-22. PubMed ID: 11851634
[TBL] [Abstract][Full Text] [Related]
39. CYP2D6 gene variants in urban/admixed and Amerindian populations of Venezuela: pharmacogenetics and anthropological implications.
Griman P; Moran Y; Valero G; Loreto M; Borjas L; Chiurillo MA
Ann Hum Biol; 2012 Mar; 39(2):137-42. PubMed ID: 22324840
[TBL] [Abstract][Full Text] [Related]
40. Pharmacogenetic screening of the gene deletion and duplications of CYP2D6.
Meijerman I; Sanderson LM; Smits PH; Beijnen JH; Schellens JH
Drug Metab Rev; 2007; 39(1):45-60. PubMed ID: 17364880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
